Flamel secures $4M from Glaxo for cardiovascular product line

Justine Varieur Cadet | March 27, 2009 | Cardiovascular Business | Structural Heart Disease

Flamel Technologies has earned an additional $4 million milestone from GlaxoSmithKline (GSK) pursuant to its Micropump license agreement for Coreg CR (carvedilol phosphate extended release capsules).

The Lyon, France-based Flamel said its Coreg CR was launched by the London-based GSK in 2007 and is indicated for use in treating three cardiovascular conditions:

Hypertension;
Post-MI left ventricular dysfunction; and
Mild to severe heart failure.

The company said its Coreg CR microparticles are produced by Flamel Technologies at its production facility in Pessac, France, using its Micropump technology platform,

"Flamel is engaged in 18 feasibility study programs with seven of the top twenty pharmaceutical companies," said Stephen H. Willard, Flamel's CEO.

Justine Varieur Cadet

Around the web

Health Imaging

Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Flamel secures $4M from Glaxo for cardiovascular product line

Related Content

Around the web